1512P Assessing the impact of anti PD-1/PD-L1 inhibitors on cancer care health and budget in Ireland

Abstract

In Ireland, the incidence of cancer was estimated to be 30,272 in 2018, with the incidence expected to rise over the next 5 years by 39% in males and 27% in females. Despite chemotherapy being considered the standard of care (SOC) in many malignancies, it is associated with high levels of toxicity. Immunuotherapy has revolutionized cancer care, offering improved health outcomes. Many treatment options with the potential for use in several cancer types has led to concerns around the long-term affordability of these products.